19 Apr April WIN-Madison meeting features emerging cancer drug and treatment firms
MADISON – Three examples of Wisconsin’s growing cluster of cancer drug development and treatment companies will be featured at the Tuesday, April 28 luncheon meeting of the Wisconsin Innovation Network in Madison.
A number of Madison-area companies, as well as related research institutions, are working on cancer drug and treatment initiatives. Leaders of three early stage companies will share their progress.
Shawn Guse, CEO of Compact Particle Acceleration Corp., which is developing a compact proton therapy system for the treatment of cancer using dielectric-wall accelerator technology. CPAC is a spin-off of TomoTherapy, one of a handful of companies worldwide that makes specialized radiation machines for treating cancer.
Laura Strong, president and COO of Quintessence Biosciences, a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. Quintessence recently began Phase 1 clinical trials of a human protein that has been genetically modified to be toxic to cancer cells.
Jim Prudent, founder and CEO of Centrose, which enhances drugs with specialized sugars. Centrose is pioneering scientific breakthroughs in the understanding of sugar chemistry and sugar biology in order to rapidly develop a diverse pipeline of proprietary therapeutics.
Lunch will be held April 28 starting at 11:30 a.m. with the presentation at 12:30 at the Sheraton Hotel on John Nolen Drive in Madison. Contact the Wisconsin Technology Council for more information.